In 2021, multinational pharmaceutical companies begin to accelerate the adjustment of their business models

6667px;text-align:justify;white-space:normal;'>

6667px;text-align:justify;white-space:normal;'>

6667px;text-align:justify;white-space:normal;'>Recently, an internal email from Eli Lilly China was exposed in the industry.
The content of the e-mail revealed that Eli Lilly China decided to adjust the sales and regional marketing teams of Ou Tangjing, as well as the hybrid sales teams of Xinbaida, Cial, and Futaiao (ie CCO hybrid teams) to actively respond to changes in the external environment.
, Continue to promote the strategic transformation of China's business.
According to Eli Lilly, the reason for the adjustment of Ou Tangjing’s team was mainly because Ou Tangjing was not included in the fourth batch of national centralized procurement catalogs.
In order to cope with the increasing market challenges, the Lilly Diabetes Alliance Division started Adjust business models and focus on core mature markets.

6667px;text-align:justify;white-space:normal;'>Recently, an internal email from Eli Lilly China was exposed in the industry.
The content of the e-mail revealed that Eli Lilly China decided to adjust the sales and regional marketing teams of Ou Tangjing, as well as the hybrid sales teams of Xinbaida, Cial, and Futaiao (ie CCO hybrid teams) to actively respond to changes in the external environment.
, Continue to promote the strategic transformation of China's business.
According to Eli Lilly, the reason for the adjustment of Ou Tangjing’s team was mainly because Ou Tangjing was not included in the fourth batch of national centralized procurement catalogs.
In order to cope with the increasing market challenges, the Lilly Diabetes Alliance Division started Adjust business models and focus on core mature markets.
6667px;text-align:justify;white-space:normal;'>It is understood that in February this year, in the fourth batch of bids for 10mg of Engligliflozin, the original researcher Boehringer Ingelheim/Lilly was still out after a 24% drop.
Engligliflozin was won by 4 domestic companies.
6667px;text-align:justify;white-space:normal;'>In this regard, the industry believes that due to the influence of volume purchases, Eli Lilly has made the decision to abandon the maintenance and development of Ou Tangjing’s non-core markets and focus on Ou Tangjing’s existing mature markets in the future.
6667px;text-align:justify;white-space:normal;'>In this context, it has become a matter of course that the originally formulated job configuration will gradually be adjusted, the team structure will be optimized, and the staff will be laid off.
6667px;text-align:justify;white-space:normal;'>As early as early January this year, there was news from Eli Lilly in China that it would further deepen the transformation of its retail business business model, and no longer retain the CAILI and retail product divisions and no longer establish a full-time retail store sales team.
, The future will focus on the five key disease areas of cancer, immunity, diabetes, pain and neurodegenerative diseases.
6667px;text-align:justify;white-space:normal;'>In fact, under the influence of centralized domestic procurement, many multinational pharmaceutical companies are accelerating the adjustment of their business models by focusing on core market promotion, optimizing product lines, and laying off employees.
6667px;text-align:justify;white-space:normal;'>For example, at the beginning of the year, Merck announced the adjustment arrangements for the new year’s leadership team: Since January 18, Han Jason, the current head of the digital interaction and transformation department, has been appointed to lead the diabetes division, retail and distributor management teams.
Cui Xiaoling succeeded; in addition, the pricing, commercial insurance and KAM parts were put under the management of market access and public policy leader Wang Xiaoye, thus forming a new government affairs and market access team.
6667px;text-align:justify;white-space:normal;'> 
6667px;text-align:justify;white-space:normal;'>
6667px;text-align:justify;white-space:normal;'> 
6667px;text-align:justify;white-space:normal;'>
6667px;text-align:justify;white-space:normal;'> 
6667px;text-align:justify;white-space:normal;'>
6667px;text-align:justify;white-space:normal;'> 
6667px;text-align:justify;white-space:normal;'>On March 17, Pfizer China and WuXi Biologics, an open biopharmaceutical technology platform company, announced an acquisition agreement.

WuXi Biologics will acquire Pfizer China's biopharmaceutical production base in Hangzhou, and relevant employees will also be taken over by WuXi Biologics.
According to data, the acquired biopharmaceutical production base covers an area of ​​50,000 square meters and was put into GMP production in 2018, including a raw liquid production line and two preparation production lines.
The transaction is expected to be completed in the first half of 2021.
6667px;text-align:justify;white-space:normal;'>Recently, Bristol-Myers Squibb (China) Pharmaceutical Co.
, Ltd.
"drug business license" has also been actively cancelled.
6667px;text-align:justify;white-space:normal;'>In this regard, BSM explained that it was because the subsidiary mainly focused on warehousing business after its establishment, but due to policy changes in the domestic drug circulation field, the company chose to stop the relevant business of the aforementioned Wuxi subsidiary.

6667px;text-align:justify;white-space:normal;'>In general, affected by the normalization of centralized procurement, multinational pharmaceutical companies have been under significant pressure in recent years.
In order to cope with this pressure and actively strive for the Chinese market, multinational pharmaceutical companies have become more and more likely to adjust their sales teams and abolish pharmaceutical representatives.
Come more frequently.
In the future, it will become the norm to focus more on core business by divesting non-core assets.